Navigation Links
Global Genitourinary Drugs Market 2011-2015 Report Reveals That One of the Major Challenges Is the Increase in the Patent Expiries of the Best-Selling Drugs in the Market
Date:12/3/2013

DUBLIN, December 3, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/67g6vc/global) has announced the addition of the "Global Genitourinary Drugs Market 2011-2015" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

TechNavio's analysts forecast the Global Genitourinary Drugs market to grow at a CAGR of 3.05 percent over the period 2011-2015. One of the key factors contributing to this market growth is the entry of novel biological drugs. The Global Genitourinary Drugs market has also been witnessing a paradigm shift toward biological drugs. However, lack of adherence to medication could pose a challenge to the growth of this market.

The key vendors dominating this space are Abbott Laboratories, Astellas Pharma Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline plc, Merck and Co. Inc., and Pfizer Inc.

Other vendors mentioned in the report are Agile Therapeutics Inc., Allergan Inc., Antares Pharma Inc., Boehringer Ingelheim GmbH, Dong-A Pharmaceutical Co. Ltd., Detrol LA, Ferring Holding S.A., Kissei Pharmaceutical Co. Ltd., Merck Serono S.A., Novartis International AG, Novo Nordisk A/S, Nymox Pharmaceutical Corp., PregLem S.A., Recordati S.p.A., Rottapharm S.p.A., Teva Pharmaceutical Industries Ltd., VIVUS Inc., Warner Chilcott plc, and Watson Pharmaceuticals Inc.

Commenting on the report, an analyst from TechNavio's Healthcare team said: "Patients suffering from infections and disorders related to genitourinary systems are using steroids and immunosuppressants. However, these medications cause serious side effects because they are chemically synthesized. Hence, patients are turning to biological drugs that not only cause fewer side effects, but are also more effective in the treatment of genitourinary infection. Moreover, there has been an increase in the number of biological drugs entering the Global Genitourinary Drugs market."

According to the report, one of the major growth factors driving the Global Genitourinary Drugs market is the entry of novel drugs such as Cialis which are more effective than the drugs used in multiple-drug therapies. These novel drugs provide cost-effective treatment for genitourinary infection.


For more information visit http://www.researchandmarkets.com/research/67g6vc/global

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
2. Bone Densitometers Market is Expected to Reach USD 908.5 Million Globally in 2019: Transparency Market Research
3. The Global Fund Replenishment Partners Talk Shared Responsibility
4. Spectrometers And Spectrophoto/Fluorometers - 2012 Global Strategic Business Report with Forecasts to 2018
5. Global Urological Catheters (Dialysis & Urinary) Strategic Business Report 2013-2018: Urinary Catheters Take the Lead
6. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
7. Natural Source Vitamin E (Tocopherols and Tocotrienols) - A Global Market Overview
8. InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
9. NineSigma, GE Announce Selection of 10 Finalists in GE Global 3D Printing Production Quest
10. Glenmark Announces Appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API Business
11. Global Electronics Market 2018 Forecasts for 6 Sectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):